Cutler Group’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-2,500
Closed -$2K 5564
2022
Q1
$2K Buy
+2,500
New +$98.2K ﹤0.01% 4749
2021
Q4
Sell
-11,000
Closed -$4K 5946
2021
Q3
$4K Buy
11,000
+9,800
+817% +$381K ﹤0.01% 4662
2021
Q2
$1K Sell
1,200
-1,200
-50% -$51K ﹤0.01% 5404
2021
Q1
$7K Sell
2,400
-3,100
-56% -$147K ﹤0.01% 4141
2020
Q4
$76K Sell
5,500
-300
-5% -$12.7K ﹤0.01% 1711
2020
Q3
$45K Buy
5,800
+5,300
+1,060% +$227K ﹤0.01% 1864
2020
Q2
$1K Buy
+500
New +$24.7K ﹤0.01% 4133

Other funds holding RPRX

Cutler Group's RPRX Position: Q4 2021 in Review

Cutler Group sold out of Royalty Pharma (RPRX) in Q4 2021, closing a stake of 440 shares — an estimated $17.1K sold.

Cutler Group first reported a position in RPRX in Q3 2020 and held it in 4 quarters. The position peaked at $450K in Q2 2021. 266 funds tracked by Wall St. Rank hold RPRX as of Q4 2021.

  • Cutler Group reported no remaining Royalty Pharma position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 440 Royalty Pharma shares in Q4 2021, an estimated $17.1K.
  • Cutler Group first reported a position in Royalty Pharma in Q3 2020 and held it in 4 quarters.
  • Cutler Group's Royalty Pharma position peaked at $450K in Q2 2021.
  • 266 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.